Content area
Colorectal carcinoma remains one of the primary contributors to cancer deaths; however, it is also considered a preventable type of cancer, because the prognosis of the disease is directly dependent on its timely detection. Developing accurate risk prediction models for colorectal cancer is crucial for identifying individuals at both low and high risk, as risk stratification determines the need for additional interventions, which carry their own risks. The development of new non-invasive diagnostic methods based on biomaterial analysis, alongside standard diagnostic techniques such as colonoscopy with biopsy, computed tomography scanning, and magnetic resonance imaging, can address multiple objectives: improving screening accuracy, providing a comprehensive assessment of minimal residual disease, identifying patients at a high risk of colorectal cancer, and evaluating the effectiveness of ongoing treatments. The lack of sensitive diagnostic methods drives contemporary research toward the discovery of new tools for detecting tumor cells, particularly through the examination of biological materials, including blood, exhaled air, and tumor tissue itself. In this article, we analyze current studies regarding biomarkers in colorectal cancer and prognostic significance.
Details
Volatile organic compounds--VOCs;
Minimal residual disease;
Accuracy;
Magnetic resonance imaging;
Biological materials;
Biopsy;
Cancer therapies;
Mutation;
Tumors;
Metabolism;
Biomaterials;
Colorectal cancer;
Risk;
Prediction models;
Tumor cells;
Medical prognosis;
Surgery;
Computed tomography;
Biomedical materials;
Cancer;
Biomarkers;
Colorectal carcinoma;
Methods;
Precision medicine
; Sekacheva Marina 3 ; Zaki, Fashafsha 4
; Fatyanova Anastasia 5 ; Potievskiy Mikhail 6 ; Kononova Elena 7 ; Kholstinina Anna 2 ; Polishchuk Ekatherina 2 ; Shegai, Peter 6 ; Kaprin Andrey 8 1 Russian Medical Academy of Postgraduate Education of Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency, Volokolamskoye Shosse, 91, 125371 Moscow, Russia; [email protected], P. Hertsen Moscow Oncology Research Institute—Branch or the Federal State Budgetary Institution “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, 2nd Botkinsky Proezd, 3, 125284 Moscow, Russia; [email protected]
2 Oncology Department of Antitumor Drug Therapy, Sechenov University Clinical Hospital No.4, I.M. Sechenov First Moscow State Medical University, Str. Dovatora, 15, Bldg. 2, 119048 Moscow, Russia; [email protected] (A.F.); [email protected] (A.K.); [email protected] (E.P.)
3 World-Class Reserch Centre «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), Str. Bolshaya Pirogovskaya, 6, Bldg. 1, 119991 Moscow, Russia; [email protected]
4 P. Hertsen Moscow Oncology Research Institute—Branch or the Federal State Budgetary Institution “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, 2nd Botkinsky Proezd, 3, 125284 Moscow, Russia; [email protected], The Institute for Personalized Cardiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Str. Bolshaya Pirogovskaya, 6, Bldg. 1, 119435 Moscow, Russia
5 Oncology Department of Antitumor Drug Therapy, Sechenov University Clinical Hospital No.4, I.M. Sechenov First Moscow State Medical University, Str. Dovatora, 15, Bldg. 2, 119048 Moscow, Russia; [email protected] (A.F.); [email protected] (A.K.); [email protected] (E.P.), The Department of Oncology, Radiotherapy and Reconstructive Surgery, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., Bldg. 8/2, 119991 Moscow, Russia
6 Federal State Budgetary Institution “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, 4, Koroleva Street, 249036 Obninsk, Russia; [email protected] (M.P.); [email protected] (P.S.); [email protected] (A.K.)
7 P. Hertsen Moscow Oncology Research Institute—Branch or the Federal State Budgetary Institution “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, 2nd Botkinsky Proezd, 3, 125284 Moscow, Russia; [email protected]
8 Federal State Budgetary Institution “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, 4, Koroleva Street, 249036 Obninsk, Russia; [email protected] (M.P.); [email protected] (P.S.); [email protected] (A.K.), Peoples’ Friendship University of Russia—RUDN University, Miklukho-Maklaya Str. Bld. 6, 117198 Moscow, Russia